Drugs / Bacille Calmette Guerin tuberculosis vaccine
Trials 0
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Comparator or background therapy1 trial | ||||||
| Phase 2 | NCT01231503 Background | Jan 2011 → Apr 2014 | malaria | GlaxoSmithKline | Completed | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Bacille Calmette Guerin tuberculosis vaccine | “Bacille Calmette Guerin tuberculosis vaccine” NCT01231503 ↗ |
| Known as | BCG | ClinicalTrials.gov intervention name — accepted as the source's own label NCT01231503 ↗ |
| Modality | Vaccine | “Bacille Calmette Guerin tuberculosis vaccine (BCG)” NCT01231503 ↗ |
| Route | Other | “The BCG vaccine was administered via intradermal route in the shoulder.” NCT01231503 ↗ |